Estrogen does not restore bone lost after ovariectomy in the rat

Area of Science:

• Endocrinology
• Bone Biology
• Pharmacology

Background:

• Estrogen plays a crucial role in bone metabolism.
• Estrogen deficiency, such as after ovariectomy, leads to significant bone loss.
• Previous findings indicated 17 beta-estradiol (E2) suppresses bone resorption and stimulates bone formation.

Purpose of the Study:

• To investigate if 17 beta-estradiol (E2) treatment can restore bone lost after ovariectomy in rats.
• To compare the effects of E2 alone and in combination with other bone-active agents on bone volume and formation.

Main Methods:

• Ovariectomy was performed on 13-week-old rats.
• Following ovariectomy, rats received treatments including E2, human calcitonin (hCT), (3-amino-1-hydroxypropylidene)-1-bisphosphonate (AHPrBP), or combinations thereof for 8 weeks.
• Bone volume and histodynamic indices of bone formation were assessed at the tibial metaphysis.

Main Results:

• Ovariectomized rats showed approximately 40% less bone volume compared to controls.
• Treatments with E2, hCT, or AHPrBP resulted in only a slight, non-significant increase in bone volume compared to untreated ovariectomized rats.
• E2 did not enhance the bone volume increase achieved by hCT or AHPrBP alone, suggesting its effect is limited to inhibiting bone resorption.
• Bone formation indices were suppressed by E2, hCT, and AHPrBP treatments.

Conclusions:

• Estrogen deficiency in rats causes bone loss that is preventable by estrogen administration.
• Estrogen administration is unable to restore bone that has already been lost due to estrogen deficiency.
• Rat and human bone exhibit similar responses to estrogen deficiency and estrogen administration regarding bone loss and restoration.